Skip to main content
Premium Trial:

Request an Annual Quote

Mobidiag Inks UK Distribution Deal With YouMed

NEW YORK (GenomeWeb) – Finnish molecular diagnostics firm Mobidiag has signed a distribution and commercialization deal with YouMed for its PCR-based Amplidiag platform.

Under the terms of the agreement, YouMed will sell and market Amplidiag and its associated menu of in vitro diagnostic tests for gastrointestinal infections, including bacterial, viral, and parasitic infections. The distribution agreement also includes the upcoming, automated Amplidiag Easy system.

Financial and other terms of the agreement were not disclosed.

"There is an unmet need in the UK molecular diagnostic market for accurate, reliable testing for gastrointestinal pathogens. We are confident the Mobidiag assays and systems can have a positive impact on management of patients suffering from these infections," YouMed Managing Director Christopher Brain said in a statement.

Mobidiag CEO Tuomas Tenkanen added that expanding its distribution network to include the UK was an important step for the company. Since the beginning of September, the company has also announced new distribution deals for Sweden and Norway, Central and Eastern Europe, and Portugal

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.